1. Home
  2. LPA vs ESPR Comparison

LPA vs ESPR Comparison

Compare LPA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LPA

Logistic Properties of the Americas

HOLD

Current Price

$3.41

Market Cap

79.0M

Sector

N/A

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$2.75

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPA
ESPR
Founded
2013
2008
Country
United States
United States
Employees
N/A
294
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.0M
731.9M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
LPA
ESPR
Price
$3.41
$2.75
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.60
AVG Volume (30 Days)
15.3K
4.8M
Earning Date
03-18-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
N/A
$2.92
Revenue Next Year
N/A
N/A
P/E Ratio
$11.25
N/A
Revenue Growth
N/A
21.31
52 Week Low
$2.04
$0.73
52 Week High
$9.41
$4.18

Technical Indicators

Market Signals
Indicator
LPA
ESPR
Relative Strength Index (RSI) 74.10 45.18
Support Level $2.51 $2.66
Resistance Level $3.60 $3.02
Average True Range (ATR) 0.20 0.18
MACD 0.09 0.04
Stochastic Oscillator 77.03 63.00

Price Performance

Historical Comparison
LPA
ESPR

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: